Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT04815096

Imaging Immune Activation in COVID-19

Led by CellSight Technologies, Inc. · Updated on 2026-05-08

80

Participants Needed

1

Research Sites

389 weeks

Total Duration

On this page

Sponsors

C

CellSight Technologies, Inc.

Lead Sponsor

U

University of California, San Francisco

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a single center, single arm exploratory imaging study involving up to two intravenous microdoses of \[18F\]F-AraG (the second tracer dose is optional) followed by whole-body PET-CT imaging in participants with convalescent COVID-19. Up to 80 participants will be enrolled over an accrual period of approximately 48 months.

CONDITIONS

Official Title

Imaging Immune Activation in COVID-19

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age >18 years
  • Ability to read and understand written informed consent document
  • Recent diagnosis of SARS-CoV-2 infection confirmed by positive nucleic acid test from respiratory samples
  • More than 14 days since onset of COVID-19 symptoms or since initial positive test if no symptoms
  • Laboratory tests within 60 days prior showing platelet count ≥75,000/mm3, absolute neutrophil count >1000/mm3, AST <3 times upper limit of normal, ALT <3 times upper limit of normal, and creatinine clearance ≥60 mL/min estimated by Cockcroft-Gault equation
Not Eligible

You will not qualify if you...

  • Any medical condition that would interfere with imaging acquisition as judged by the investigator
  • Pregnant women or breastfeeding participants
  • Female participants of reproductive potential without a negative pregnancy test within 24 hours before imaging and not using two forms of birth control (excluding withdrawal or timing methods)
  • History of allogeneic stem cell or solid organ transplant
  • Laboratory abnormalities: neutrophil count <1000 cells/mm3, platelet count <75,000 cells/mm3, hemoglobin <8 mg/dL, creatinine clearance <60 mL/min, AST >3 times upper limit of normal, ALT >3 times upper limit of normal
  • Known SARS-CoV-2 viral shedding within 5 days before PET imaging
  • Prior diagnosis of myelodysplasia syndrome or lymphoproliferative disease
  • Active systemic autoimmune diseases unrelated to COVID-19
  • COVID-19 vaccination before the first PET imaging session
  • Prior PET scan or therapeutic radiation within 1 year before enrollment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of California, San Francisco

San Francisco, California, United States, 94110

Actively Recruiting

Loading map...

Research Team

T

Timothy Henrich, MD

CONTACT

K

Kofi Asare

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here